Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781323 | 1.00 | PTGER2 (0.52) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL29369796 | 0.96 | PTGER2 (0.58) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13017435 | 0.93 | MAPT (0.56) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13063089 | 0.93 | PTGER2 (0.51) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL3660760 | 0.91 | ALDH1A1 (0.55) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13063092 | 0.90 | PTGER2 (0.50) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL3050603 | 0.88 | PTGER2 (0.52) | PTGER2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13017411 | 0.88 | PTGER2 (0.52) | PTGER2MAPTNPC1RAB9AKMT2A | |
| SCHEMBL13133135 | 0.87 | KMT2A (0.57) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29372302 | 0.87 | PTGER2 (0.67) | PTGER2MAPTNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288043-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | Jenivision Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20230372274-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | JENIVISION INC (US) | 2023-11-23 | — | — | US | claimed |
| CN-117062602-A | Compositions and methods for periorbital administration of EP2 receptor agonists | 杰尼视界公司 | 2023-11-14 | — | — | CN | claimed |
| US-20230285347-A1 | Preterm Labour with Prostaglandin E2 Receptor Agonists | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2023-09-14 | — | — | US | claimed |
| WO-2022170112-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | JENIVISION INC. (US) | 2022-08-11 | — | — | WO | claimed |
| EP-3337474-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | Jenivision Inc. (US) | 2018-06-27 | — | — | EP | claimed |
| US-9820954-B2 | Quantitative peri-orbital application of ophthalmology drugs | JENIVISION INC. (US) | 2017-11-21 | — | — | US | claimed |
| WO-2017031137-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. (US) | 2017-02-23 | — | — | WO | claimed |
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | JENIVISION INC. | 2017-02-23 | — | — | US | claimed |
| US-20240041832-A1 | METHODS AND COMPOSITIONS FOR TREATING EYE DISEASES | JENIVISION INC (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4288043-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | Jenivision Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230372274-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | JENIVISION INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372274-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | JENIVISION INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372274-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | JENIVISION INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-2238101-A2 | DIFLUOROBIPHENYLAMIDE DERIVATIVES FOR THE TREATMENT OF OCULAR HYPERTENSION | ASTERAND UK LIMITED (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010111449-A1 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100247606-A1 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247606-A1 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2009098458-A2 | BIARYL AMIDES | ASTERAND UK LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098458-A2 | BIARYL AMIDES | ASTERAND UK LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049734-A1 | QUANTITATIVE PERI-ORBITAL APPLICATION OF OPHTHALMOLOGY DRUGS | PTGIR, QDPR, PDE3A | PTGER2 129/4885MAPT 3711/4885NPC1 1914/4885 |
| US-20100247606-A1 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS | VEGFA, PGF, GHRHR | PTGER2 400/4885MAPT 781/4885NPC1 1665/4885 |
| US-20240041832-A1 | METHODS AND COMPOSITIONS FOR TREATING EYE DISEASES | EYA3, LIPA, PDE6C | PTGER2 422/4885MAPT 1125/4885NPC1 30/4885 |
| US-20230372274-A1 | COMPOSITIONS AND METHODS FOR PERIORBITAL ADMINISTRATION OF EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, PTGIR | PTGER2 1/4885MAPT 4231/4885NPC1 1036/4885 |
| US-20230285347-A1 | Preterm Labour with Prostaglandin E2 Receptor Agonists | PTGER2, PTGIR, PTGDR2 | PTGER2 1/4885MAPT 4463/4885NPC1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.